| Uzoamaka O Nwoye, MD | |
|
5955 Zeamer Ave, 673d Mdg, Elmendorf Afb, AK 99506-3702 | |
| (907) 580-1240 | |
| Not Available |
| Full Name | Uzoamaka O Nwoye |
|---|---|
| Gender | Female |
| Speciality | Urology |
| Location | 5955 Zeamer Ave, Elmendorf Afb, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801093026 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 24826 (Nebraska) | Primary |
| Entity Name | Alaska Native Tribal Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437189339 PECOS PAC ID: 6709780265 Enrollment ID: O20031125000772 |
News Archive
Depending on the age of asthmatic children, on their exposure to molds or dampness in their bedroom, and on the severity of their asthma, vitamin C has greater or smaller beneficial effect against asthma, according to a study published in the Clinical and Translational Allergy.
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that its investigational biopharmaceutical product, MP4CO, has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA) for use in treating acute painful sickling crises in patients with sickle cell disease.
The zebrafish, a translucent fish often used as a model of human development and disease, offers unique advantages for studying the cause, growth, and spread of tumors using strategies and methods presented in the current "Cancer Biology" special issue of Zebrafish, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The entire issue is available free online at www.liebertpub.com/zeb
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Uzoamaka O Nwoye, MD 5955 Zeamer Ave, 673d Mdg, Elmendorf Afb, AK 99506-3702 Ph: (907) 580-1240 | Uzoamaka O Nwoye, MD 5955 Zeamer Ave, 673d Mdg, Elmendorf Afb, AK 99506-3702 Ph: (907) 580-1240 |
News Archive
Depending on the age of asthmatic children, on their exposure to molds or dampness in their bedroom, and on the severity of their asthma, vitamin C has greater or smaller beneficial effect against asthma, according to a study published in the Clinical and Translational Allergy.
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that its investigational biopharmaceutical product, MP4CO, has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA) for use in treating acute painful sickling crises in patients with sickle cell disease.
The zebrafish, a translucent fish often used as a model of human development and disease, offers unique advantages for studying the cause, growth, and spread of tumors using strategies and methods presented in the current "Cancer Biology" special issue of Zebrafish, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The entire issue is available free online at www.liebertpub.com/zeb
Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.
› Verified 7 days ago